Market Cap 4.72B
Revenue (ttm) 383.48M
Net Income (ttm) -146.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.17%
Debt to Equity Ratio 0.00
Volume 1,119,300
Avg Vol 957,480
Day's Range N/A - N/A
Shares Out 57.35M
Stochastic %K 11%
Beta 0.77
Analysts Strong Sell
Price Target $122.46

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 367 9600
Fax: 949 367 9984
Address:
One Glaukos Way, Aliso Viejo, United States
TrendSnatch
TrendSnatch Sep. 15 at 9:32 AM
$GKOS Competitive space; differentiation and margin improvement matter
0 · Reply
JarvisFlow
JarvisFlow Sep. 10 at 11:00 AM
BTIG has updated their rating for Glaukos ( $GKOS ) to Buy with a price target of 118.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 11:28 AM
$GKOS Outstanding article that hits the mark on GKOS's current state. So if you want to refresh your GKOS insights or learn about GKOS from scratch, this is a must read. https://beyondspx.com/quote/GKOS/analysis/glaukos-pioneering-interventional-glaucoma-amidst-market-headwinds-gkos
0 · Reply
erkdg
erkdg Sep. 2 at 5:20 PM
$GKOS are we still expecting FDA approval within next 6 weeks? I couldnt find info whether its on track or postponed.
2 · Reply
ZacksResearch
ZacksResearch Sep. 2 at 2:22 PM
$GKOS: Record-breaking first-half 2025 revenue growth, but hurdles remain! 🚀 Glaukos posted a 27.3% YoY revenue increase, fueled by the iDose TR implant's success. However, reimbursement complexities and execution risks could impact near-term momentum ⚠️. See what challenges and opportunities lie ahead for GKOS 👉 https://www.zacks.com/stock/news/2746029/glaukos-builds-dual-growth-engines-amid-market-headwinds?cid=sm-stocktwits-2-2746029-body-10439&ADID=SYND_STOCKTWITS_TWEET_2_2746029_BODY_10439
0 · Reply
ZacksResearch
ZacksResearch Sep. 2 at 1:22 PM
$GKOS just raised revenue guidance 🚀 Record 1H sales driven by iDose TR adoption + strong international glaucoma growth are powering dual engines even with market headwinds. Full breakdown here 👉 https://www.zacks.com/stock/news/2746029/glaukos-builds-dual-growth-engines-amid-market-headwinds?cid=sm-stocktwits-2-2746029-teaser-10438&ADID=SYND_STOCKTWITS_TWEET_2_2746029_TEASER_10438
0 · Reply
CandleRise
CandleRise Aug. 27 at 6:31 AM
$GKOS momentum slowing down, needs strength to push higher.
1 · Reply
Kingofstocks0001
Kingofstocks0001 Aug. 20 at 4:47 AM
$GKOS This will double in 1 year snd triple in 2 years
0 · Reply
bvr91
bvr91 Aug. 14 at 9:08 PM
$GKOS Started my position here at 86.01. So far so good 🤞
0 · Reply
Kingofstocks0001
Kingofstocks0001 Aug. 14 at 7:10 PM
$GKOS to the moon
0 · Reply
Latest News on GKOS
Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:15 AM EDT - 6 weeks ago

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript


Glaukos Announces Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 7 weeks ago

Glaukos Announces Second Quarter 2025 Financial Results


Glaukos Announces Participation in Upcoming Investor Conferences

May 13, 2025, 7:00 AM EDT - 4 months ago

Glaukos Announces Participation in Upcoming Investor Conferences


Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 10:05 PM EDT - 5 months ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript


Glaukos Announces First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 5 months ago

Glaukos Announces First Quarter 2025 Financial Results


Glaukos Announces the Release of its 2024 Sustainability Report

Apr 16, 2025, 7:00 AM EDT - 5 months ago

Glaukos Announces the Release of its 2024 Sustainability Report


Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 24, 2025, 7:00 AM EST - 7 months ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™


Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 21, 2025, 4:29 AM EST - 7 months ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript


Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 23, 2024, 7:00 AM EST - 9 months ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™


Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 21, 2024, 7:04 AM EST - 9 months ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High


Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:03 PM EST - 11 months ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript


Glaukos Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 11 months ago

Glaukos Announces Third Quarter 2024 Financial Results


Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:57 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript


Glaukos Announces Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Second Quarter 2024 Financial Results


Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

May 1, 2024, 8:42 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript


Glaukos Announces First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2024 Financial Results


Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 11:13 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript


TrendSnatch
TrendSnatch Sep. 15 at 9:32 AM
$GKOS Competitive space; differentiation and margin improvement matter
0 · Reply
JarvisFlow
JarvisFlow Sep. 10 at 11:00 AM
BTIG has updated their rating for Glaukos ( $GKOS ) to Buy with a price target of 118.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 11:28 AM
$GKOS Outstanding article that hits the mark on GKOS's current state. So if you want to refresh your GKOS insights or learn about GKOS from scratch, this is a must read. https://beyondspx.com/quote/GKOS/analysis/glaukos-pioneering-interventional-glaucoma-amidst-market-headwinds-gkos
0 · Reply
erkdg
erkdg Sep. 2 at 5:20 PM
$GKOS are we still expecting FDA approval within next 6 weeks? I couldnt find info whether its on track or postponed.
2 · Reply
ZacksResearch
ZacksResearch Sep. 2 at 2:22 PM
$GKOS: Record-breaking first-half 2025 revenue growth, but hurdles remain! 🚀 Glaukos posted a 27.3% YoY revenue increase, fueled by the iDose TR implant's success. However, reimbursement complexities and execution risks could impact near-term momentum ⚠️. See what challenges and opportunities lie ahead for GKOS 👉 https://www.zacks.com/stock/news/2746029/glaukos-builds-dual-growth-engines-amid-market-headwinds?cid=sm-stocktwits-2-2746029-body-10439&ADID=SYND_STOCKTWITS_TWEET_2_2746029_BODY_10439
0 · Reply
ZacksResearch
ZacksResearch Sep. 2 at 1:22 PM
$GKOS just raised revenue guidance 🚀 Record 1H sales driven by iDose TR adoption + strong international glaucoma growth are powering dual engines even with market headwinds. Full breakdown here 👉 https://www.zacks.com/stock/news/2746029/glaukos-builds-dual-growth-engines-amid-market-headwinds?cid=sm-stocktwits-2-2746029-teaser-10438&ADID=SYND_STOCKTWITS_TWEET_2_2746029_TEASER_10438
0 · Reply
CandleRise
CandleRise Aug. 27 at 6:31 AM
$GKOS momentum slowing down, needs strength to push higher.
1 · Reply
Kingofstocks0001
Kingofstocks0001 Aug. 20 at 4:47 AM
$GKOS This will double in 1 year snd triple in 2 years
0 · Reply
bvr91
bvr91 Aug. 14 at 9:08 PM
$GKOS Started my position here at 86.01. So far so good 🤞
0 · Reply
Kingofstocks0001
Kingofstocks0001 Aug. 14 at 7:10 PM
$GKOS to the moon
0 · Reply
TaoistTrader
TaoistTrader Aug. 9 at 7:09 PM
$GKOS Interested in building a position here ...
0 · Reply
d_risk
d_risk Aug. 4 at 10:58 PM
$GKOS - Glaukos Corporation Common Stock - 10Q - Updated Risk Factors GKOS risk factors in 2025 show expanded detail on sales volatility from Medicare changes, orphan drug competition, international regulatory and geopolitical risks, heightened legal and cybersecurity threats including AI, new debt-related risks, refined trade and reimbursement challenges, plus added anti-takeover and exclusive forum provisions; several outdated risks removed, but core themes remain. #MedicareChanges #Anti-TakeoverProvisions #ReimbursementChallenges #TradeChallenges #DebtRisks #AIRisks #LegalAndCybersecurityThreats #GeopoliticalRisks #InternationalRegulatoryRisks #OrphanDrugCompetition 🟢 Added 🟠 Removed https://d-risk.ai/GKOS/10-Q/2025-08-04
1 · Reply
FractionalShareWhale
FractionalShareWhale Jul. 31 at 8:50 PM
$GKOS 🔥👐🏽🔥
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 6:33 PM
Glaukos sheds 2.2% after Q2 results — but is there a silver lining? 💡 📈 Revenue up 29.7% YoY on a reported basis, beating estimates by 8.1% 💰 Raised 2025 sales guidance; promising pipeline progress continues 📉 Headwinds persist from policy-related pressures See what makes $GKOS a potential buy 👉 https://www.zacks.com/stock/news/2644985/gkos-stock-falls-despite-q2-earnings-revenues-beat-guidance-raised?cid=sm-stocktwits-2-2644985-body-5262&ADID=SYND_STOCKTWITS_TWEET_2_2644985_BODY_5262
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 4:56 PM
$GKOS beat Q2 earnings and raised guidance — so why is the stock dropping? Revenue surged, but the ongoing operating loss is still dragging sentiment. Full breakdown here 👉 https://www.zacks.com/stock/news/2644985/gkos-stock-falls-despite-q2-earnings-revenues-beat-guidance-raised?cid=sm-stocktwits-2-2644985-teaser-5184&ADID=SYND_STOCKTWITS_TWEET_2_2644985_TEASER_5184
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jul. 30 at 1:58 PM
$GKOS about to explode
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jul. 25 at 9:08 PM
$GKOS to the moon
0 · Reply
ZacksResearch
ZacksResearch Jul. 9 at 1:46 PM
Is $GKOS a hidden gem in the eye care sector? 👁️ 🚀 Q1 revenues soared 25% YoY, fueled by the iDose TR implant's strong uptake, and full-year guidance remains robust. 🌍 International interventional glaucoma sales up 15%, with promising adoption of MIGS tech as a global standard. See what makes the investment case strong for GKOS 👉 https://www.zacks.com/stock/news/2568730/glaukos-ramps-up-idose-tr-battles-legacy-and-reimbursement-risks?cid=sm-stocktwits-2-2568730-body-1036&ADID=SYND_STOCKTWITS_TWEET_2_2568730_BODY_1036
0 · Reply
ZacksResearch
ZacksResearch Jul. 9 at 11:44 AM
$GKOS crushed Q1 on iDose TR strength — but is the party already over? Record-breaking sales from iDose TR drove the quarter, but looming reimbursement issues and legacy product declines could pressure the near-term outlook. Full breakdown of the risks and momentum here 👉 https://www.zacks.com/stock/news/2568730/glaukos-ramps-up-idose-tr-battles-legacy-and-reimbursement-risks?cid=sm-stocktwits-2-2568730-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2568730_TEASER
0 · Reply
DonCorleone77
DonCorleone77 Jun. 25 at 9:38 PM
$GKOS Glaukos announces E.U. MDR certification for iStent infinite The company states: "Glaukos announced it has received European Union Medical Device Regulation certification for iStent infinite, along with several of its other leading micro-invasive glaucoma surgery technologies, including iStent inject W. Glaukos' iStent trabecular micro-bypass stenting platform primarily involves the insertion of a micro-scale surgical devices designed to reduce intraocular pressure by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma."
0 · Reply
Estimize
Estimize Jun. 19 at 12:03 PM
Wall St is expecting -0.26 EPS for $GKOS Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/gkos?chart=historical&metric_name=eps&utm_c
0 · Reply
JarvisFlow
JarvisFlow Jun. 18 at 10:00 AM
Mizuho updates rating for Glaukos ( $GKOS ) to Neutral, target set at 115 → 140.
0 · Reply